共 189 条
[1]
Ma Z(2010)Global tuberculosis drug development pipeline: the need and the reality Lancet 375 2100-2109
[2]
Lienhardt C(2012)New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future J Infect Dis 205 S241-S249
[3]
McIlleron H(2012)Innovative trial designs are practical solutions for improving the treatment of tuberculosis J Infect Dis 205 S250-S257
[4]
Nunn AJ(2011)Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit Trials 12 81-4371
[5]
Wang X(2008)Multi-arm clinical trials of new agents: some design considerations Clin Cancer Res 14 4368-1214
[6]
Lienhardt C(2009)Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial Trials 10 39-280
[7]
Raviglione M(2008)Speeding up the evaluation of new agents in cancer J Natl Cancer Inst 100 1204-338
[8]
Spigelman M(2009)Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis Am J Respir Crit Care Med 180 273-1189
[9]
Hafner R(2006)Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis Am J Respir Crit Care Med 174 331-1282
[10]
Jaramillo E(2009)Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial Lancet 373 1183-53